Robert J Romanelli1, Vani Nimbal1, Sarah K Dutcher2, Xia Pu2, Jodi B Segal3. 1. 1 Palo Alto Medical Foundation Research Institute, Palo Alto, CA, USA. 2. 2 Office of Generic Drugs, United States Food and Drug Administration, Silver Springs, MD, USA. 3. 3 Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Abstract
BACKGROUND: Despite the availability of generic levothyroxine products for more than a decade, uptake of these products is poor. OBJECTIVE: We sought to evaluate determinants of generic prescribing of levothyroxine. METHODS: In a cross-sectional analysis of electronic health records data between 2010 and 2013, we identified adult patients with a levothyroxine prescription from a primary-care physician (PCP) or endocrinologist. We used mixed-effect logistic regression models with random intercepts for prescribing provider to examine predictors of generic levothyroxine prescribing. Models include patient, prescription, and provider fixed-effect covariates. Odds ratios (ORs) and 95% CIs were generated. Between-provider random variation was quantified by the intraclass correlation coefficient (ICC). RESULTS: Study patients (n = 63 838) were clustered among 941 prescribing providers within 25 ambulatory care clinics. The overall prevalence of generic prescribing of levothyroxine was 73%. In the multivariable mixed-effect model, patients were significantly less likely to receive generic levothyroxine from an endocrinologist than a PCP (OR = 0.43; 95% CI = 0.33-0.55; P < 0.001). Women were less likely to receive generic levothyroxine than men from endocrinologists (OR = 0.68; 95% CI = 0.59-0.78; P < 0.001) but not from PCPs. Between-provider variation in generic prescribing was 18.3% in the absence of fixed-effect covariates and could be explained marginally by patient, prescription, and provider factors (ICC = 15.9%). CONCLUSIONS: Generic levothyroxine prescribing differed by PCPs and endocrinologists. Residual variation in generic prescribing, after accounting for measurable factors, indicates the need for provider interventions or patient education aimed at improving levothyroxine generic uptake.
BACKGROUND: Despite the availability of generic levothyroxine products for more than a decade, uptake of these products is poor. OBJECTIVE: We sought to evaluate determinants of generic prescribing of levothyroxine. METHODS: In a cross-sectional analysis of electronic health records data between 2010 and 2013, we identified adult patients with a levothyroxine prescription from a primary-care physician (PCP) or endocrinologist. We used mixed-effect logistic regression models with random intercepts for prescribing provider to examine predictors of generic levothyroxine prescribing. Models include patient, prescription, and provider fixed-effect covariates. Odds ratios (ORs) and 95% CIs were generated. Between-provider random variation was quantified by the intraclass correlation coefficient (ICC). RESULTS: Study patients (n = 63 838) were clustered among 941 prescribing providers within 25 ambulatory care clinics. The overall prevalence of generic prescribing of levothyroxine was 73%. In the multivariable mixed-effect model, patients were significantly less likely to receive generic levothyroxine from an endocrinologist than a PCP (OR = 0.43; 95% CI = 0.33-0.55; P < 0.001). Women were less likely to receive generic levothyroxine than men from endocrinologists (OR = 0.68; 95% CI = 0.59-0.78; P < 0.001) but not from PCPs. Between-provider variation in generic prescribing was 18.3% in the absence of fixed-effect covariates and could be explained marginally by patient, prescription, and provider factors (ICC = 15.9%). CONCLUSIONS: Generic levothyroxine prescribing differed by PCPs and endocrinologists. Residual variation in generic prescribing, after accounting for measurable factors, indicates the need for provider interventions or patient education aimed at improving levothyroxine generic uptake.
Entities:
Keywords:
electronic health records; generic prescribing; levothyroxine
Authors: Jacqueline Jonklaas; Antonio C Bianco; Andrew J Bauer; Kenneth D Burman; Anne R Cappola; Francesco S Celi; David S Cooper; Brian W Kim; Robin P Peeters; M Sara Rosenthal; Anna M Sawka Journal: Thyroid Date: 2014-12 Impact factor: 6.568
Authors: Jefferson P Lomenick; Lulu Wang; Steve B Ampah; Benjamin R Saville; Fayrisa I Greenwald Journal: J Clin Endocrinol Metab Date: 2013-01-04 Impact factor: 5.958
Authors: Jeffrey R Garber; Rhoda H Cobin; Hossein Gharib; James V Hennessey; Irwin Klein; Jeffrey I Mechanick; Rachel Pessah-Pollack; Peter A Singer; Kenneth A Woeber Journal: Endocr Pract Date: 2012 Nov-Dec Impact factor: 3.443
Authors: Jeremi M Carswell; Joshua H Gordon; Erica Popovsky; Andrea Hale; Rosalind S Brown Journal: J Clin Endocrinol Metab Date: 2012-12-21 Impact factor: 5.958
Authors: Nan Huo; Li Chen; Ahmed Ullah Mishuk; Chao Li; Richard A Hansen; Ilene Harris; Zippora Kiptanui; Zhong Wang; Sarah K Dutcher; Jingjing Qian Journal: Endocrine Date: 2020-01-28 Impact factor: 3.633